- Home
- ETON
as 12-18-2024 12:36pm EST
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | DEER PARK |
| Market Cap: | 199.5M | IPO Year: | 2018 |
| Target Price: | $15.00 | AVG Volume (30 days): | 242.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.03 - $13.98 | Next Earning Date: | 11-12-2024 |
| Revenue: | $34,677,000 | Revenue Growth: | 5.64% |
| Revenue Growth (this year): | 23.05% | Revenue Growth (next year): | 81.27% |
Stock Insider Trading Activity of Eton Pharmaceuticals Inc. (ETON)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | ETON | 10% Owner | Oct 23 '24 | Buy | $7.98 | 10,000 | $79,814.00 | 2,770,000 | |
| Opaleye Management Inc. | ETON | 10% Owner | Oct 4 '24 | Buy | $7.01 | 62,070 | $434,136.74 | 2,770,000 |
Latest Eton Pharmaceuticals Inc. News
ETON Breaking Stock News: Dive into ETON Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
Simply Wall St.
6 days ago
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) top owners are retail investors with 58% stake, while 26% is held by institutions
GlobeNewswire
15 days ago
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
Pharmaceutical Technology
22 days ago
Eton acquires US rights to neonatal diabetes treatment from AMMTeK
TipRanks
22 days ago
Eton Pharmaceuticals acquires U.S. rights to Amglidia from AMMTeK
MT Newswires
23 days ago
Eton Pharmaceuticals Acquires US Rights to Neonatal Diabetes Drug Amglidia
GlobeNewswire
23 days ago
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
Simply Wall St.
a month ago
Eton Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Compare ETON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ETON Eton Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.